clinical trial · NCT05687526
A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus
RemeGen Co., Ltd.·phase1·completed·n = 16
Systemic Lupus ErythematosusTelitacicept
brief summary
This is a multi-center, open-label, phase 1 study.
started
May 25, 2023
primary completion
Nov 14, 2025
completion
Nov 14, 2025
last updated
Mar 9, 2026
detailed description
The purpose of this study is to evaluate the pharmacokinetics (PK) of multiple doses of Telitacicept in subjects with childhood-onset systemic lupus erythematosus (cSLE) on a background of standard of care therapy and explore the safety and efficacy of Telitacicept in patients with cSLE.
official title
A Phase 1, Open-label, Multi-center, Multiple-dose Study to Evaluate the Pharmacokinetics of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol